Mycophenolate Mofetil

證據等級: L5

預測適應症: 10 個

Mycophenolate Mofetil: From Organ Transplant Rejection to HIV Infectious Disease

One-Sentence Summary

Mycophenolate mofetil (MMF) is a selective immunosuppressant used internationally for prevention of acute rejection in solid organ transplantation, though it currently holds no market authorization in India. The TxGNN model predicts it may be effective for HIV infectious disease, with 10 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Organ transplant rejection prophylaxis (not registered in India; based on international use)
Predicted New Indication	HIV Infectious Disease
TxGNN Prediction Score	99.86%
Evidence Level	L2
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Mycophenolate mofetil (MMF) is a prodrug hydrolyzed in vivo to mycophenolic acid (MPA), a potent and selective inhibitor of inosine monophosphate dehydrogenase (IMPDH). By blocking IMPDH, MMF depletes the intracellular deoxyguanosine triphosphate (dGTP) nucleotide pool preferentially in lymphocytes. Because HIV reverse transcriptase depends on dGTP to synthesize viral DNA, this depletion directly impairs viral replication — and has been shown in clinical studies to synergize with nucleoside analog antiretrovirals (NRTIs) such as abacavir and didanosine. Simultaneously, MMF reduces the proliferation of activated CD4⁺ T cells, which are the primary host cells permissive to HIV replication, thereby restricting the available viral reservoir.

HIV chronic infection is characterized by persistent immune hyperactivation, which paradoxically accelerates CD4⁺ T-cell depletion and disease progression. MMF’s ability to dampen this hyperactivation — independent of its direct antiviral effect — represents a second mechanistic rationale. Early clinical studies, including a Phase 4 study (MAN2) in ART-naïve patients and several Phase 2 trials in treatment-experienced patients, found that MMF was generally tolerable in HIV-infected individuals and modestly reduced viral markers when used alongside specific NRTIs.

However, a fundamental tension limits this repurposing opportunity: MMF is an immunosuppressant, and using it in a population already immunocompromised by HIV raises serious safety concerns. Adding further immunosuppression could increase the risk of opportunistic infections and impair HIV-specific immune surveillance. No clinical consensus on a minimum safe CD4⁺ threshold for MMF use in HIV has been established. Until this safety paradox is resolved with adequately powered trials, the mechanistic rationale — though compelling — cannot justify routine clinical application.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01453192	Phase 3	Completed	27	Multicenter prospective trial of renal transplantation in HIV-1 infected patients on Raltegravir-based ART; evaluated acute graft rejection at 6 months and immunological outcomes
NCT00120419	Phase 4	Unknown	90	MAN2 Study: randomized MMF vs. no treatment in ART-naïve HIV-1 patients; assessed whether MMF reduces chronic immune hyperactivation and CD4⁺ T-cell decline
NCT00038272	Phase 2	Completed	56	Randomized double-blind placebo-controlled study of DAPD vs. DAPD+MMF in treatment-experienced HIV patients; explored synergistic antiretroviral activity via dGTP depletion
NCT00247494	Phase 4	Unknown	90	Sub-study of MAN2: assessed effect of MMF on cardiovascular and metabolic surrogate markers in HIV-1 infected patients not receiving ART
NCT00112593	N/A	Completed	5	Allogeneic HSCT to induce mixed hematopoietic chimerism in HIV-positive patients using non-myeloablative conditioning; MMF used as post-transplant immunosuppression
NCT00009009	Phase 2	Completed	10	Safety and efficacy of renal transplantation in HIV-infected patients with end-stage renal disease; confirmed MMF tolerability within the HIV immunosuppressive context
NCT00021489	Phase 2	Withdrawn	0	Planned study of MMF safety, tolerability, and antiretroviral activity as adjunct to abacavir in heavily treatment-experienced patients; withdrawn prior to enrollment — no data generated

Literature Evidence

PMID	Year	Type	Journal	Key Findings
12352149	2002	Clinical Trial	J Acquir Immune Defic Syndr	MMF added to abacavir-based ART depleted intracellular dGTP and reduced plasma HIV-1 RNA in 5 patients with multidrug-resistant HIV; proof-of-concept for IMPDH inhibition as adjunctive strategy
15213566	2004	Clinical Trial	J Acquir Immune Defic Syndr	Randomized pilot (n=17) of MMF during HAART interruption in chronic HIV-1 patients; assessed viral load rebound kinetics and lymphatic tissue reservoir changes
15871638	2005	PK/PD Study	Clin Pharmacokinet	Low-dose MMF PK/PD profile in HIV patients on abacavir+efavirenz+nelfinavir; recommended therapeutic drug monitoring given pharmacokinetic interactions
15355127	2004	PK/PD Study	Clin Pharmacokinet	MMF’s effects on intracellular dCTP/dGTP pools and lamivudine triphosphate concentrations; demonstrated mechanistic rationale for NRTI synergy
16379601	2005	Clinical Study	AIDS Res Hum Retroviruses	MMF+HAART in treatment-naïve acute and chronic HIV-1 patients showed no detrimental immunological effects; longitudinal T-cell proliferation analysis
17017956	2006	Review	Curr Top Med Chem	Comprehensive mechanistic review of immunosuppressive drugs in HIV; details how IMPDH inhibition addresses chronic immune hyperactivation as a disease driver
11391161	2001	Pilot Study	J Acquir Immune Defic Syndr	Open-label pilot (n=7) of MMF+ABC+ddI+APV±EFV in patients with AIDS and ≥8 failed ART regimens; well-tolerated but no sustained viral load decline
17885292	2007	Clinical Study	AIDS	DAPD (amdoxovir) with or without MMF in drug-resistant HIV after extensive ART; evaluated safety and antiretroviral activity in treatment-experienced patients
41118390	2025	Experimental	J Clin Invest	Antiproliferative drugs selectively target HIV-infected CD4⁺ T-cell clones; provides contemporary mechanistic support for MMF’s role in reducing the clonally expanded HIV reservoir
39515757	2025	Cohort Study	Am J Transplant	Long-term kidney transplant outcomes in HIV recipients on tacrolimus/MMF; compared r-ATG vs. IL-2 receptor antagonist induction — real-world safety data for MMF in HIV patients

India Market Information

Mycophenolate mofetil currently has no authorized products registered in India (0 licenses, market status: not marketed). No approved indication text is available from CDSCO records.

Safety Considerations

Drug Interactions (92 total interactions identified; key interactions listed below):

Severity	Interacting Drug(s)	Clinical Relevance
Major	Activated charcoal	Dramatically reduces MMF absorption; avoid concurrent use
Moderate	Proton pump inhibitors (Omeprazole, Esomeprazole, Rabeprazole, Lansoprazole, Dexlansoprazole)	Reduce MPA systemic exposure; monitor drug levels and immunosuppressive efficacy
Moderate	Antibiotics (Amoxicillin, Doxycycline, Tetracycline, Clarithromycin, Minocycline, Vancomycin, Kanamycin, Paromomycin)	Disruption of gut flora may impair enterohepatic recirculation of MPA, potentially reducing MMF efficacy — particularly relevant given frequent antibiotic use in HIV patients
Moderate	Antacids (Aluminum hydroxide, Calcium carbonate, Magnesium oxide)	Chelation reduces MMF absorption; separate administration by at least 2 hours
Minor	Zinc sulfate, Zinc acetate, Iron	Minor reduction in MMF absorption

Please refer to the package insert for complete warnings and contraindications, as key warnings and contraindication data are not available in the current evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: Although MMF’s IMPDH inhibition mechanism provides a plausible and experimentally supported rationale for use in HIV, the fundamental safety paradox — deploying an immunosuppressant in an already immunocompromised population — combined with consistently small trial sizes (n=5 to 90), absence of a Phase 3 superiority trial specifically for HIV treatment, and zero India regulatory footprint, makes advancing this candidate premature without further targeted evidence generation.

To proceed, the following is needed:

Retrieve complete MOA and pharmacology data from DrugBank (DB00688) to fill the current data gap and support mechanistic analysis
Obtain full prescribing information (package insert) from an international regulatory source (FDA/EMA) to document warnings, contraindications, and pregnancy/infection risk categories
Define a minimum safe CD4⁺ T-cell threshold below which MMF use in HIV is contraindicated — this is the central unresolved safety question
Commission or identify a well-powered prospective RCT with pre-specified primary endpoints (e.g., viral reservoir size, ART-free viral suppression duration) in a defined HIV subpopulation (e.g., multidrug-resistant HIV, HIV with autoimmune complications, HIV transplant recipients)
Conduct a drug-drug interaction review specifically for MMF combined with current first-line ART regimens (INSTI-based regimens), given that 92 DDIs are already documented and antibiotic co-administration is common in HIV patients
Evaluate regulatory pathway feasibility in India through CDSCO for a potential orphan or investigational new drug application
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.